ArticleAdvances in therapy2023

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.

Min Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.